128 Batches Scheduled for Production at Plant 3 This Year
Expansion of High Titer Process Applications

Celltrion has completed the renewal of its European Good Manufacturing Practice (EU-GMP) certification for its total 250,000-liter production facilities located at the Songdo campus in Incheon. With this, the company has once again secured a stable manufacturing base to supply products reliably to the European and global markets.

Aerial view of Celltrion factory in Songdo, Incheon. The Asia Business Daily DB

Aerial view of Celltrion factory in Songdo, Incheon. The Asia Business Daily DB

View original image

According to Celltrion on September 22, this round of EU-GMP renewal covers the drug substance (DS) production facilities and drug product (DP) production facilities at the Songdo Plant 1, 2, and 3 sites, totaling a 250,000-liter capacity. EU-GMP refers to the quality control standards that manufacturing facilities must meet to supply pharmaceuticals to the European market.


In particular, as commercial production began at Songdo Plant 3 at the end of 2024, production stabilization has progressed rapidly, driving an overall increase in capacity. Celltrion plans to produce a total of 128 batches at Plant 3 this year, which is approximately a 142% increase compared to the previous year. Including the production expansion at Plant 3, the total production volume at the entire Songdo campus is expected to rise by about 15% year-over-year.


The company is also expanding in-house production of drug products. The new DP plant on the Songdo campus received approval for building use from the Incheon Free Economic Zone Authority in June, and is currently undergoing Installation Qualification (IQ) and Operational Qualification (OQ) assessments. After completing related evaluations and regulatory procedures, the plant is expected to begin commercial production.


Once the new DP plant becomes operational, the company’s drug product manufacturing capacity, which had been concentrated at the Songdo Plant 2 production line, will be expanded. Celltrion plans to further increase the proportion of in-house production from DS to DP, thereby reducing reliance on contract manufacturing organization (CMO) outsourcing, and improving schedule flexibility and quality management efficiency.


The application of high titer processes, designed to improve production yield, is also expanding. The high titer process enables the production of more antibody protein within the same culture scale, and Celltrion is currently applying it to certain products. The company aims to expand the list of products utilizing this process in the future to boost per-batch output and improve manufacturing costs.


The 66,000-liter production facility in Branchburg, New Jersey, USA, will also serve as an important hub within Celltrion’s global supply chain. The site is currently producing contract manufacturing organization (CMO) volumes for Eli Lilly, while at the same time undergoing technology transfer for the production of Celltrion’s own products.



A Celltrion official stated, “The EU-GMP renewal for the Songdo campus production facilities once again demonstrates our production base and quality competitiveness for reliably supplying products to global markets. Centering on Plant 3, we will scale up production, and further strengthen both supply stability and cost competitiveness through the new DP plant, expanded high titer processes, and utilization of our U.S. manufacturing base.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing